Approaches to lung cancer treatment using the CD3E x GP-2-directed bispecific monoclonal antibody BIS-1

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 203-206

  Kroesen, B J ^a   Nieken, J ^a   Sleijfer, D T ^a   Molema, G ^a   De Vries, E G E ^a   Groen, H J M ^a   Helfrich, W ^a   The, T H ^a   Mulder, N H ^a   De Leij, L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bispecific monoclonal antibody; CD3xEGP 2; Lung cancer

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER IMMUNOTHERAPY; CANCER MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LYMPHOCYTE TRANSFER; MALE; METASTASIS; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

AGED; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RATS; T-LYMPHOCYTES;

EID: 0030727541     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050433     Document Type: Article

References (11)

1. Dutch Pharmacopee (1983) (9th ed) SDU publishers. The Hague. ISSN:0920-6140
2. Kosterink JGW, Jonge MWA de, Smit EF, Piers DA, Kengen RAM, Postmus PE, Shochat D, Groen HJM, The TH, Leij L de (1995) Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small cell lung carcinoma. J Nucl Med 36:2356-2362
3. Kroesen BJ, Haar A ter, Spakman H, Willemse P, Sleijter DT, Vries EGE de, Mulder NH, Berendsen HH, Limburg PC, The TH, Leij L de (1993) Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody redirected T cells. Cancer Immunol Immunother 37:400-407
4. Kroesen BJ, Buter J, Sleijter DT, Janssen RAJ, Graaf W van der, The TH, Leij L de, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in patients receiving subcutanous IL-2. Br J Cancer 70:652-661
5. Kroesen BJ, Bakker A, Lier RAW van, The TH, Leij L de (1995) Bispecific antibody mediated targetcellspecific costimulation of resting T cells via CD5 and CD28. Cancer Res 55:4409-4415
6. Kroesen BJ, Helfrich W, Bakker A, Wubbena AS, Bakker H, Kal HB, The TH, Leij L de (1995) Reduction of EGP-2 positive pulmonary metastases by bispecific antibody redirected T cells in an immunocompetent rat model. Int J Cancer 61:812-818
7. Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, Leij L de (1996) The role of apoptosis in bispecific antibody-mediated T cell cytotoxicity. Br J Cancer 73:721-727
8. Kroesen BJ, Helfrich W, Molema G, Leij L de (1997) Bispecific antibodies for treatment in experimental animal models and man. Adv Drug Deliv Rev (in press)
9. Leij L de, Postmus PE, Poppema S, Elema JE, The TH (1986) The use of monoclonal antibodies for the pathological diagnosis of lung cancer. In: Hanssen HH (ed) Lung cancer: basic and clinical aspects. Martinus Nijhof, The Hague, pp 31-48
10. Leij L de, Helfrich W, Stein R, Mattes MJ (1994) SCLC cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer [Suppl] 8:60-63
11. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber P, Pichlmaier H, Hirche H, Pichlmayr R (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 343:1177-1183